Message #20 From:
NewsBot Date: August 30, 2006 05:45:00 AM
UGNE News Unigene to Present at the ThinkEquity Partners Conference; Fortical(R) Sales to Upsher-Smith Resume
FAIRFIELD, N.J.--(BUSINESS WIRE)--Aug. 30, 2006--Unigene Laboratories, Inc.'s (OTCBB: UGNE) President and CEO, Dr. Warren Levy, will speak at the 4th Annual ThinkEquity Partners Conference on Tuesday, September 12, 2006 at 9:00AM PDT. Dr. Levy will present information on the Company's products and collaborations to analysts, portfolio managers, investment bankers and other financial professionals. The conference will be held at The Ritz-Carlton Hotel in San Francisco from September 11-14, 2006.
Separately, Unigene reports that as expected and previously disclosed, sales of its nasal calcitonin product Fortical(R) to its U.S. marketing partner, Upsher-Smith Laboratories, have resumed. "Going forward, we expect to experience a more regular ordering pattern for Fortical from our partner," commented Warren P. Levy, President and CEO of Unigene.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(R) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.
